These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33616651)

  • 1. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.
    Clark RE; Apperley JF; Copland M; Cicconi S
    Blood Adv; 2021 Feb; 5(4):1102-1109. PubMed ID: 33616651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
    Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
    Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
    Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of Ph
    Ansari S; Verma M
    Med Oncol; 2023 Jul; 40(8):237. PubMed ID: 37439908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
    Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
    Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
    Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
    J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
    Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
    Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
    Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.
    Alswied A; Rehman A; Lai LW; Duran J; Sardar M; Proytcheva MA
    Cancer Genet; 2021 Apr; 252-253():111-114. PubMed ID: 33497941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations.
    Xue M; Cheng J; Zhao J; Zhang S; Jian J; Qiao Y; Liu B
    Int J Lab Hematol; 2019 Feb; 41(1):94-101. PubMed ID: 30285321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
    Luatti S; Castagnetti F; Marzocchi G; Baldazzi C; Gugliotta G; Iacobucci I; Specchia G; Zanatta L; Rege-Cambrin G; Mancini M; Abruzzese E; Zaccaria A; Grimoldi MG; Gozzetti A; Ameli G; Capucci MA; Palka G; Bernasconi P; Palandri F; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; Testoni N;
    Blood; 2012 Jul; 120(4):761-7. PubMed ID: 22692507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
    Wang PP; Zhang PP; Zhang J; Xi YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of predictive effect of European treatment and outcome study long term survival score on survival outcomes in children with chronic myeloid leukemia of chronic phase].
    Zheng FY; Deng RZ; Lu AD; Jia YP; Zeng HM; Zhang LP; Jiang Q
    Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):956-961. PubMed ID: 39327962
    [No Abstract]   [Full Text] [Related]  

  • 18. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
    Johansson B; Fioretos T; Mitelman F
    Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate.
    Siti Mariam I; Norhidayah R; Zulaikha AB; Nazihah MY; Rosline H; Kausar GA; Sarina S; Azlan H; Ankathil R
    Front Oncol; 2022; 12():720845. PubMed ID: 36003793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.